TheEdgeResearch
Home / Stocks / HPST

Hempstract, Inc. (HPST)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.03 ▲ +2.04%
Market Cap
$25.5M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
1.79
52-Wk Range
0.0019-0.0448
CEO
Ronald M. Herzfeld
Country
US
Currency
USD

Hempstract, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Warden, WA, US. The stock last traded at $0.03, up 2.04% on the session, giving a market capitalisation of $25.5M. On trailing twelve-month figures it carries a trailing P/E of -33.33, a net margin of 0.0%. Its beta of 1.79 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-33.33
Price / Sales
0.00
Price / Book
-25.37
EV / EBITDA
-47.03
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-1.42
Current ratio
0.21
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
2
IPO date
2021-01-08
Headquarters
Warden, WA, US
About Hempstract, Inc.

Operating across the United States, Hempstract, Inc. develops and supplies products centered around cannabidiol (CBD) and cannabigerol (CBG). Its catalog features CBD in isolate powder form, alongside various distillate oils. The enterprise adopted the Hempstract, Inc. moniker in November 2020, having previously been known as Riverdale Oil and Gas Corporation. This firm maintains its principal office in Warden, Washington.

Comparable companies

Hempstract, Inc. is most often compared with the following Healthcare names:

ATHJFBFFTFCHBRFCQCQGENHGRAMFIBXNFMKEAFPMXSFVNNYF
More research on HPST
HPST technical analysis HPST TheEdge Score Compare against peers
Open full interactive analysis & DCF →